An important announcement from Clementia
The IFOPA is pleased to share this announcement from Clementia Pharmaceuticals: Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with FOP. Read more.
The National Organization for Rare Disorders (NORD) named Dr. Fred Kaplan among its 2017 honorees.
Potentially Promising Treatment for FOP
We are pleased to share a few exciting updates on our ongoing work to help improve the lives of people with FOP.Read more
21st Century Cures Legislation Signed by President Obama
On December 7, the Senate followed the House of Representative's lead and signed the 21st Century Cures bill which is focused on developing treatments and cures for rare diseases; President Obama signed it on December 13.Read more
Approval of 3 New Sites!
The participation of individuals living with FOP in clinical studies and trials is key to FOP drug development efforts.Read more
Phase 2 Trial Webinar
We hope you’ll join us Wednesday, Nov. 30, 2016, 11 am to noon Eastern Time, for an important webinar presented by Clementia on the top-line results from the phase 2 trial of palovarotene for treatment of patients with fibrodysplasia ossificans progressiva.Read more
Please read Clementia's Clinical Program Announcement: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study. Click here.